MIF Invests in Triumvira Immunologics to Advance Novel (TAC)-T Cell Therapy for the Treatment of Multiple Myeloma

March 17, 2022

The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced an investment in Triumvira Immunologics (“Triumvira”), an Austin, TX-based clinical-stage biotech developing novel, targeted autologous and allogeneic T cell immunotherapies that co-opt the natural biology of T cells to treat solid tumors and blood cancers.